Rosete Beatrice E, Wendel Danielle, Horslen Simon P
Department of Pharmacy, Seattle Children's Hospital, Seattle, WA, USA.
School of Pharmacy, University of Washington, Seattle, WA, USA.
Expert Rev Gastroenterol Hepatol. 2021 Jul;15(7):727-733. doi: 10.1080/17474124.2021.1913052. Epub 2021 Apr 26.
: The goal for pediatric short bowel syndrome (SBS) patients is intestinal adaptation. Until recently, the medical management of pediatric SBS has centered on the prevention and treatment of complications in order to allow time for adaptation. Teduglutide, glucagon-like peptide 2 (GLP-2) analog, has recently been approved for use in pediatric SBS patients greater than 1 year of age as a novel agent to augment intestinal adaptation. : This article reviews the pharmacology, safety, efficacy, and tolerability of GLP-2 analog teduglutide in pediatric patients greater than 1 year of age. We review all current studies and discuss teduglutide's place in pediatric SBS therapy. : Teduglutide marks the first successful pharmacological intervention that augments the natural process of adaptation safely and effectively in SBS pediatric patients. More studies and further development are needed to optimize its potential in other pediatric patients.
小儿短肠综合征（SBS）患者的目标是实现肠道适应。直到最近，小儿SBS的药物治疗一直围绕并发症的预防和治疗展开，以便为肠道适应留出时间。替度鲁肽，一种胰高血糖素样肽2（GLP-2）类似物，最近已被批准用于1岁以上的小儿SBS患者，作为增强肠道适应的新型药物。本文综述了GLP-2类似物替度鲁肽在1岁以上小儿患者中的药理学、安全性、有效性和耐受性。我们回顾了所有当前的研究，并讨论了替度鲁肽在小儿SBS治疗中的地位。替度鲁肽标志着首次成功的药物干预，可安全有效地增强SBS小儿患者的自然适应过程。需要更多的研究和进一步的开发来优化其在其他小儿患者中的潜力。
